IMV Inc.

IMV is a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases (RSV, COVID-19). IMV is leveraging its unique delivery platform (DPX) that programs immune cells directly within the human body to produce rapid, robust, and sustained target killing capabilities. IMV’s lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating best-in-class results in ovarian cancer and DLBCL (Diffuse Large B Cell Lymphoma). It is evaluated in multiple Phase 2 clinical trials across six indications and also in combination with Merck’s Keytruda® in two clinical trials. IMV has the potential to make history and successfully develop the first effective in vivo T cell therapy for cancer. IMV is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts.